Annals of Allergy, Asthma & Immunology · Nov 2026
GLP-1 RECEPTOR AGONISTS AND ASTHMA OUTCOMES IN PATIENTS WITH OBESITY: A SYSTEMATIC REVIEW AND META-ANALYSIS
By Bitar A, Qaryouti H, Jereisat R et al.
Introduction Obesity is associated with frequent asthma exacerbations and poor disease control. Glucagon-like peptide-1 (GLP-1) receptor agonists may improve asthma through weight reduction and anti-inflammatory effects. We evaluated their association with asthma outcomes in patients with overweight or obesity. Methods A PRISMA-conformant systematic search of PubMed/MEDLINE, Embase, Cochrane CENTRAL, Web of Science, Scopus, ClinicalTrials.gov, and major conference proceedings were systematically searched through June 2026. Comparative studies enrolling patients with asthma and overweight or obesity were included. Random-effects models pooled risk ratios for exacerbations, while other effect measures were synthesized separately. Risk of bias was assessed using ROBINS-I. Results Five retrospective cohort studies involving more than 73,000 participants met the inclusion criteria. Three obesity-specific cohorts demonstrated fewer asthma exacerbations with GLP-1 receptor agonists (pooled risk ratio 0.73; 95% CI 0.66–0.81; I²=70%). Benefit was observed in adults without diabetes and adolescents with overweight or obesity. Among adolescents, treatment was associated with fewer asthma-related emergency department visits (risk ratio 0.42; 95% CI 0.19–0.95) and systemic corticosteroid prescriptions (risk ratio 0.66; 95% CI 0.54–0.81). A large obesity cohort demonstrated improved risk-domain and overall asthma control (odds ratios 2.12 and 2.10), without a significant difference in exacerbation odds. Risk of bias ranged from moderate to serious, and adverse-event reporting was insufficient for pooled analysis. Conclusion GLP-1 receptor agonist use was associated with fewer asthma exacerbations and improved asthma control in patients with overweight or obesity. Prospective randomized trials are needed to confirm these findings and further characterize safety.